The European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) have revised their recommendations on the use of omega-3 polyunsaturated fatty acids (PUFA) for TG lowering and added the apoC3 inhibitor, volanesorsen, as a possible treatment option for patients with familial chylomicronaemia syndrome (FCS).1
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
